Retatrutide for Type 2 Diabetes: Blood Sugar and A1C Benefits

Retatrutide in Type 2 Diabetes

While retatrutide has garnered the most attention for its dramatic weight loss results, its effects on blood sugar control in type 2 diabetes are equally impressive. The drug's triple-agonist mechanism provides comprehensive glycemic management through multiple complementary pathways.

Phase 1b Trial: First Evidence in Diabetes

The first clinical evidence of retatrutide's glycemic effects came from a Phase 1b, multicenter, double-blind, placebo-controlled trial published in The Lancet in 2022. This multiple-ascending-dose study enrolled people with type 2 diabetes and tested doses ranging from 0.5 mg to 12 mg administered once weekly.

Key findings included dose-dependent reductions in HbA1c and fasting blood glucose, with the pharmacokinetic profile supporting once-weekly dosing. The study established the safety foundation for larger trials [1].

Phase 2 Trial: Robust Glycemic Improvements

The Phase 2 trial, published in The Lancet in 2023, was a randomized, double-blind, placebo and active-controlled (dulaglutide 1.5 mg), parallel-group study in 281 adults with type 2 diabetes. Participants received retatrutide at doses of 0.5 mg, 4 mg (two escalation regimens), 8 mg, or 12 mg for 36 weeks [2].

A1C Reductions

• Placebo: -0.01% change in A1C
• Dulaglutide 1.5 mg (active control): -1.41%
• Retatrutide 0.5 mg: -0.43%
• Retatrutide 4 mg: -1.39% to -1.30%
• Retatrutide 8 mg: -1.99%
• Retatrutide 12 mg: -1.91%

At the 8 mg and 12 mg doses, retatrutide achieved A1C reductions approaching 2%, which is clinically highly significant. The 8 mg dose appeared to have the optimal glycemic efficacy, with the 12 mg dose showing slightly less A1C reduction — possibly because higher glucagon receptor activation at the top dose partially offsets the glucose-lowering effects.

Proportion Reaching A1C Targets

• A1C <7.0%: 71-82% of participants in the 8-12 mg groups
• A1C <5.7% (normal range): 26-34% of participants in the 8-12 mg groups

Achieving normal A1C levels (<5.7%) in over a quarter of participants with type 2 diabetes is a remarkable outcome, suggesting near-complete glycemic normalization in a substantial proportion of patients.

Weight Loss in Diabetes Patients

Concurrent weight loss was substantial:

• 12 mg dose: -16.9% body weight at 36 weeks
• 8 mg dose: -16.4% body weight

These weight loss figures in people with type 2 diabetes are particularly notable because diabetes medications often cause weight gain, and even effective GLP-1 agonists typically produce less weight loss in diabetic populations compared to non-diabetic individuals.

Phase 3 Results: TRANSCEND-T2D-1

In March 2026, Eli Lilly announced topline results from TRANSCEND-T2D-1, the first Phase 3 trial of retatrutide in type 2 diabetes. This large-scale study confirmed the Phase 2 findings:

• Primary endpoint: Retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks
• Weight loss: The 12 mg dose group lost an average of 16.8% of body weight (approximately 36.6 pounds)
• A1C <7.0%: Achieved by a majority of participants across dose groups

These Phase 3 results are consistent with the Phase 2 data and confirm retatrutide's dual efficacy for both glycemic control and weight management in type 2 diabetes.

How Triple Agonism Benefits Diabetes

The three receptor targets each contribute to glycemic control:

1. GLP-1 receptor: Enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces postprandial glucose excursions
2. GIP receptor: Amplifies insulin secretion and may improve beta-cell function
3. Glucagon receptor: While glucagon raises hepatic glucose output, in the context of retatrutide's balanced profile, the weight loss and metabolic improvements driven by glucagon receptor activation indirectly improve insulin sensitivity

The net effect is comprehensive glycemic management that addresses multiple pathophysiological defects of type 2 diabetes simultaneously [3].

Comparison with Current Standards

Retatrutide's glycemic efficacy is competitive with the best available diabetes medications:

• Metformin: A1C reduction ~1.0-1.5%
• Semaglutide 1.0 mg: A1C reduction ~1.5-1.8%
• Tirzepatide 15 mg: A1C reduction ~2.0-2.4%
• Retatrutide 8-12 mg: A1C reduction ~1.7-2.0%

While tirzepatide may have a slight edge in pure glycemic control, retatrutide offers the additional benefit of superior liver fat reduction and potentially greater weight loss.

References

1. Urva S, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial." The Lancet. 2022;400(10366):1869-1881. PubMed: 36354040

2. Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet. 2023;402(10401):529-544. PubMed: 37385280

3. Doggrell SA. "Retatrutide showing promise in obesity (and type 2 diabetes)." Expert Review of Endocrinology & Metabolism. 2023;18(6):495-498. PubMed: 37947489